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Introduction
Induction of inactive disease (ID) in Juvenile Idiopathic
Arthritis (JIA) is the main target of all current regimes, as
it will maintain physical ability and hinder disease asso-
ciated-damage. Early predictive markers for the future
achievement of ID in patients under expensive therapies
are therefore urgently needed in the era of financial
recession. Our previous published experience reported
that ≥ 50% of the JIA patients achieved Clinical Remis-
sion (CR) following ≥12-month (CR12) Etanercept (ETN)
administration.
Objectives
To assess the early ID following 12 weeks-ETN treatment
(eID) and explore the eID’s prognostic value for the
CR12.
Methods
JIA patients treated with ETN for ≥12 months during the
last decade were enrolled in the study. Baseline, 12 week
and 12 month disease assessments were built on: a) the
Juvenile Arthritis Disease Activity Score (JADAS) and b)
the fulfilment of Minimal Disease Activity (MDA) and
Inactive Disease (ID) definitions, as well as CR according
to Wallace’s criteria.
Results
52 JIA patients (F:40) with a median age of 8.8 years at
first ETN dose, mainly with a polyarticular course (47)
and a median disease duration of 4.04 years were studied.
eID was achieved in 26/52 (50%) of the patients and CR12
in 28/52 (53.84%). The following factors were found to be
independent of eID: disease duration (p = 0.23), JIA classi-
fication and course (p = 0.51, p = 0.58, respectively), age
at first ETN dose (p = 0.26), presence of ANA or RF
(p = 0.43, p = 0.37, respectively) and JADAS at baseline
(p = 0.12). Interestingly, the 3 levels of disease activity
(persistent activity, MDA and ID) 3 months post-treat-
ment were associated with the 12 month post-treatment
JADAS and CR (p = 0.001 and p ≤ 0.001, respectively).
Conclusion
ETN achieved Inactive Disease in 50% of the patients
within a-12 week administration and CR in the 54% of all
patients after 12 months of therapy. These findings con-
cord with recent publications. However, neither demo-
graphic nor JIA characteristics were found to be predictors
of eID. Finally, the beneficial 3 month impact of ETN was
evidenced by its association with CR12. The disease regres-
sion proves the drug’s early efficacy in JIA patients and
supports the clinician’s management decision regarding
the application of expensive medication in the era of finan-
cial recession.
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